ELVN-001 is a small molecule commercialized by Enliven Therapeutics, with a leading Phase I program in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). According to Globaldata, it is involved in 4 clinical trials, of which 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of ELVN-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for ELVN-001 is expected to reach an annual total of $73 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ELVN-001 Overview

ELVN-001 is under development for the treatment of chronic myeloid leukemia with and without T315I mutations and Parkinson's Disease (PD). The therapeutic candidate is administered through oral route. The drug candidate acts by targeting BCR-Abl

Enliven Therapeutics Overview

Enliven Therapeutics, formerly a Imara, is a clinical-stage precision oncology company that discovers and develops small molecule kinase inhibitors. The company product pipeline includes ELVN- 001 and ELVN- 002. Its product treats chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC) and solid tumors. Enliven Therapeutics pipeline program includes BCR-ABL and HER2 which carries out gene fusion, oncogenic, small molecule inhibitors and HER2 mutations including exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). The company includes ABL 1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Enliven Therapeutics is headquartered in Boulder, Colorado, the US.
The operating loss of the company was US$83.5 million in FY2023, compared to an operating profit of US$0.7 million in FY2022. The net loss of the company was US$71.6 million in FY2023, compared to a net profit of US$1.5 million in FY2022.

For a complete picture of ELVN-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.